论文部分内容阅读
目的探讨新辅助化疗在局部晩期宫颈癌中的应用价值。方法选取2010年3月至2013年11月我院收治的局部晚期宫颈癌患者58例,随机分为两组,对照组患者直接进行手术治疗,观察组患者在行术前新辅助化疗,后行手术治疗,比较两组患者的治疗效果、手术时间、盆腔淋巴结转移、留置尿管时间与并发症情况。结果观察组患者的治疗效果优于对照组,差异有统计学意义(P<0.05)。观察组患者的并发症发生率、手术时间、盆腔淋巴结转移率均低于对照组,差异均有统计学意义(均P<0.05)。结论局部晚期宫颈癌的治疗中,在术前采用新辅助化疗,可提高临床疗效,降低术后并发症发生率,同时还可有效控制盆腔淋巴结转移率,提高患者的生存质量。
Objective To investigate the value of neoadjuvant chemotherapy in locally advanced cervical cancer. Methods Fifty-eight patients with locally advanced cervical cancer admitted to our hospital from March 2010 to November 2013 were randomly divided into two groups. Patients in the control group were treated directly with neoadjuvant chemotherapy before operation Surgical treatment, the treatment effect of two groups were compared, operation time, pelvic lymph node metastasis, indwelling catheter time and complications. Results The treatment effect of the observation group was better than that of the control group, the difference was statistically significant (P <0.05). The complication rate, operation time and pelvic lymph node metastasis rate in observation group were lower than those in control group (all P <0.05). Conclusion In the treatment of locally advanced cervical cancer, neoadjuvant chemotherapy before operation can improve the clinical curative effect and reduce the incidence of postoperative complications. It can also effectively control the pelvic lymph node metastasis rate and improve the quality of life of patients.